Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Company Performance - Amgen's stock closed at $272.11, with a daily increase of 0.99%, underperforming the S&P 500 which gained 1% [1] - Over the past month, Amgen's shares increased by 3.15%, outperforming the Medical sector's decline of 1.36% and the S&P 500's drop of 2.14% [1] Upcoming Earnings - Amgen is set to release its earnings on February 4, 2025, with an expected EPS of$ 5.02, reflecting a growth of 6.58% year-over-year [2] - The consensus estimate for quarterly revenue is $8.85 billion, indicating a 7.92% increase compared to the same quarter last year [2] Analyst Estimates - Changes in analyst estimates for Amgen are crucial as they often reflect short-term business dynamics, with positive revisions signaling a favorable business outlook [3] Valuation Metrics - Amgen has a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 13.23, which is lower than the industry average of 21.97 [5] - The company has a PEG ratio of 2.75, compared to the industry average of 1.43, indicating a higher expected earnings growth rate relative to its price [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Amgen, has a Zacks Industry Rank of 56, placing it in the top 23% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]